title: Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
abstract: OBJECTIVE
  Different methods for contouring target volumes are currently in use in the UK when irradiating glioblastomas post operatively. Both one- and two-phase techniques are offered at different centres. 90% of relapses are recognised to occur locally when using radiotherapy alone. The objective of this evaluation was to determine the pattern of relapse following concomitant radiotherapy with temozolomide (RT-TMZ).
  
  
  METHODS
  A retrospective analysis of patients receiving RT-TMZ between 2006 and 2010 was performed. Outcome data including survival were calculated from the start of radiotherapy. Analysis of available serial cross-sectional imaging was performed from diagnosis to first relapse. The site of first relapse was defined by the relationship to primary disease. Central relapse was defined as progression of the primary enhancing mass or the appearance of a new enhancing nodule within 2 cm.
  
  
  RESULTS
  105 patients were identified as receiving RT-TMZ. 34 patients were not eligible for relapse analysis owing to either lack of progression or unsuitable imaging. Patterns of first relapse were as follows: 55 (77%) patients relapsed centrally within 2 cm of the original gadolinium-enhanced mass on MRI, 13 (18%) patients relapsed >4 cm from the original enhancement and 3 (4%) relapsed within the contralateral hemisphere.
  
  
  CONCLUSIONS
  Central relapse remains the predominant pattern of failure following RT-TMZ. Single-phase conformal radiotherapy using a 2-cm margin from the original contrast-enhanced mass is appropriate for the majority of these patients.
  
  
  CONCLUSIONS
  Central relapse remains the predominant pattern of failure following chemoradiotherapy for glioblastomas.
authors: Hall-Edwards Radiotherapy Research Group, Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK. Jennifer.Sherriff@nhs.net
authors: J
authors: J
authors: Sherriff
authors: J
authors: J
authors: Tamangani
authors: L
authors: L
authors: Senthil
authors: G
authors: G
authors: Cruickshank
authors: D
authors: D
authors: Spooner
authors: B
authors: B
authors: Jones
authors: C
authors: C
authors: Brookes
authors: P
authors: P
authors: Sanghera
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000378:metabolism*; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods* / Q000401:mortality; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D020266:Radiotherapy, Conformal / Q000379:methods / Q000401:mortality; D012189:Retrospective Studies; D000077204:Temozolomide; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
references: J Neurosurg. 1983 Feb;58(2):159-69
references: 6294260
references: J Clin Oncol. 2009 Mar 10;27(8):1275-9
references: 19188675
references: Clin Oncol (R Coll Radiol). 2012 Apr;24(3):216-27
references: 21783349
references: Technol Cancer Res Treat. 2012 Jun;11(3):211-20
references: 22376134
references: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S28-35
references: 20171514
references: Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1347-50
references: 2557310
references: J Neurosurg. 1999 Aug;91(2):251-60
references: 10433313
references: Neurology. 1980 Sep;30(9):907-11
references: 6252514
references: J Clin Oncol. 2013 Nov 10;31(32):4085-91
references: 24101040
references: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7
references: 20171513
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S36-41
references: 20171516
references: Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50
references: 17306935
references: Clin Oncol (R Coll Radiol). 2011 Apr;23(3):189-98
references: 21288703
references: Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):79-88
references: 9989517
references: Int J Radiat Oncol Biol Phys. 1992;24(1):55-7
references: 1512163
references: Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9
references: 2542195
references: Radiother Oncol. 2010 Dec;97(3):377-81
references: 20855119
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1147-55
references: 20207495
references: Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
references: 20399036
references: N Engl J Med. 2009 Feb 19;360(8):765-73
references: 19228619
references: J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):143-50
references: 8708681